All Posts
$550,000 in research grants awarded by the Cholangiocarcinoma Foundation
The Cholangiocarcinoma Foundation, a nonprofit organization funding novel research for bile duct cancer, has awarded the tenth cycle of funding…
The 2024 Mark R. Clements Award announced at the 11th Annual Cholangiocarcinoma Foundation Conference
https://www.youtube.com/watch?v=HN1xJQgl0Bw The Cholangiocarcinoma Foundation announced its 2024 Mark R. Clements Award honorees at its annual Salt Lake City, Utah conference.…
4th Annual Cholangiocarcinoma Foundation Poster Abstract Awards
The Cholangiocarcinoma Foundation announced the 2024 Poster Abstract Awards at its annual conference that took place virtually and in person…
Softball Tournament Promotes Community Spirit and Builds on Special Memories
The second annual Cholangiocarcinoma Awareness Softball Tournament organized by the Bryant Family was held in March 2024 in Colonial Heights,…
Winter 2023-2024 Community Fundraiser Highlights
This winter, our Community Fundraisers created new ways to raise funds for much-needed research and programs and to shine a…
Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of care therapy alone for advanced HER2 positive biliary tract cancer
Study Name Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against…
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Study Name A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects…
Scientific Update: Webinar Recap - Immunotherapy Insights for Cholangiocarcinoma
In a CCF webinar, Dr. Haley Ellis provided an overview of recent advances in immunotherapy for cholangiocarcinoma. These cutting-edge therapies…
Cholangiocarcinoma Awareness Month Highlights 2024
Awareness Month 2024 was the most inspiring yet! Thank you to all who participated in Cholangiocarcinoma Awareness Month this past…
Scientific Update: FGFR2 Pathway Activation as a Therapeutic Biomarker for FGFR2 Inhibitors
Fibroblast growth factor receptor 2 (FGFR2) is among cholangiocarcinoma's most frequently altered genes. Chromosomal fusions and gene rearrangements are particularly…